Asset Allocation Update: Chinese Equities rise, so does our Equity Allocation

The renaissance of the competitiveness of the Chinese IT sector and the first steps to overcome the real estate crisis in the People's Republic of China open up new perspectives. In our Asset Allocation Update for March, we are increasing our equity allocation via emerging markets and taking profits in other areas.

Text: Nicola Grass

0%
Dr. Anja Hochberg comments on the Asset Allocation Update for the month of March.

What adjustments have we made to the portfolios?

Chinese equities have risen by 26% since the DeepSeek news at the end of January. Tech companies continue to deliver strong earnings, and the Chinese government now seems to recognize the importance of these firms. Valuations remain attractive despite the price increase (P/E EM 12 vs. 19 globally).

The Australian economy is robust, and the unemployment rate at 4% is too low for significant rate cuts. The Australian dollar is likely to benefit from the high interest rate level (4.1% policy rate). Therefore, we are swapping EUR government bonds for AUD government bonds and taking advantage of the yield differential of around 2%.

On the currency side, we continue to expect a depreciation of the expensive US dollar and a strong appreciation of the undervalued yen. Policy rates in Japan are likely to continue rising, unlike the rest of the world, as inflation is already at 4%. We do not expect a sustainable appreciation of the euro. The EUR/CHF rate is likely to remain below 0.95.

Despite strong fundamentals and very attractive valuations, US small caps are underperforming. Initially, it was inflation concerns, now weaker economic data is weighing on them. We are pulling the stop-loss and waiting for a better entry point.

Our overweight in Cat Bonds has generated a performance of 30% over the past two years. However, the yield premium has fallen from 10% to below 6%. We still believe Cat Bonds belong in a mixed portfolio, but after this run, we are reducing our overweight for tactical reasons.

Chinese equities have risen by 26% since the DeepSeek news at the end of January. Tech companies continue to deliver strong earnings, and the Chinese government now seems to recognize the importance of these firms. Valuations remain attractive despite the price increase (P/E EM 12 vs. 19 globally).

Despite strong fundamentals and very attractive valuations, US small caps are underperforming. Initially, it was inflation concerns, now weaker economic data is weighing on them. We are pulling the stop-loss and waiting for a better entry point.

The Australian economy is robust, and the unemployment rate at 4% is too low for significant rate cuts. The Australian dollar is likely to benefit from the high interest rate level (4.1% policy rate). Therefore, we are swapping EUR government bonds for AUD government bonds and taking advantage of the yield differential of around 2%.

Our overweight in Cat Bonds has generated a performance of 30% over the past two years. However, the yield premium has fallen from 10% to below 6%. We still believe Cat Bonds belong in a mixed portfolio, but after this run, we are reducing our overweight for tactical reasons.

On the currency side, we continue to expect a depreciation of the expensive US dollar and a strong appreciation of the undervalued yen. Policy rates in Japan are likely to continue rising, unlike the rest of the world, as inflation is already at 4%. We do not expect a sustainable appreciation of the euro. The EUR/CHF rate is likely to remain below 0.95.

Deepseek Boosts Chinese Equities

European equity markets continued to rise in February, while the American Magnificent 7, or "Mag7," have been moving sideways so far this year. However, Chinese equity prices, particularly IT stocks, have risen significantly. One of the main drivers is the announcement of the advantages of DeepSeek over other AI systems at the end of January. Confidence was also boosted by the meeting between President Xi Jinping and the CEOs of Chinese technology companies. This seems to have marked a turnaround for technology stocks (+26%).

Chinese Equities Revive Emerging Market Stocks

In recent years, China's heavy weighting, with a drawdown of 64% (MSCI China February 2021 – October 2022), has been a significant drag on emerging market equities. However, there now seems to be some movement in the Far East. Western investors' purchases have increased significantly since mid-January, and the previously extremely negative sentiment is brightening.

Indexed performance. Source: Bloomberg

As positioning among Western investors remains low and valuations are comparatively attractive, the catch-up rally could continue. Therefore, we are increasing our overweight in emerging markets.

Mag7 Still Underweight, Switch in Government Bonds

Within global equities, we are reducing our small-cap bias. While we remain underweight in the Mag7, we are now playing the better market breadth primarily through financials, UK, US mid-caps, and emerging markets.

In bonds, we are swapping euro government bonds for Australian government bonds. The yield level is significantly higher there (4.4% yield vs. 2.5% yield), and we see appreciation potential for the Australian dollar. Our underweight in CHF and corporate bonds remains.

US Dollar's Ascent Nears

Its End The dominance of the US in economic growth and stock market performance is waning, and Trump's tariff shock is priced in. The interest rate advantage over Japan continues to shrink, and we expect a USD/JPY rate of 140, which corresponds to a further appreciation of the yen by 6%.

Tactical Asset Allocation in March 2025

Relative weighting vs. Strategic Asset Allocation (SAA) in % in February and March 2025 (Source: Zürcher Kantonalbank, Asset Management)

Legal Notice

“BLOOMBERG®” and the Bloomberg indices listed herein (the “Indices”) are service marks of Bloomberg Finance L.P. and its affiliates, including Bloomberg Index Services Limited (“BISL”), the administrator of the Indices (collectively, “Bloomberg”) and have been licensed for use for certain purposes by the distributor hereof (the “Licensee”). Bloomberg is not affiliated with Licensee, and Bloomberg does not approve, endorse, review, or recommend the financial products named herein (the “Products”). Bloomberg does not guarantee the timeliness, accuracy, or completeness of any data or information relating to the Products.

Categories

Investment Strategy